142 related articles for article (PubMed ID: 23043264)
1. Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
Moynihan HA; Derrick I; Broadbear JH; Greedy BM; Aceto MD; Harris LS; Purington LC; Thomas MP; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2012 Nov; 55(22):9868-74. PubMed ID: 23043264
[TBL] [Abstract][Full Text] [Related]
2. 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.
Nieland NP; Rennison D; Broadbear JH; Purington L; Woods JH; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2009 Nov; 52(21):6926-30. PubMed ID: 19842669
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
[TBL] [Abstract][Full Text] [Related]
4. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
5. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
6. 3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
Derrick I; Neilan CL; Andes J; Husbands SM; Woods JH; Traynor JR; Lewis JW
J Med Chem; 2000 Aug; 43(17):3348-50. PubMed ID: 10966754
[TBL] [Abstract][Full Text] [Related]
7. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
8. Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.
Rennison D; Neal AP; Cami-Kobeci G; Aceto MD; Martinez-Bermejo F; Lewis JW; Husbands SM
J Med Chem; 2007 Oct; 50(21):5176-82. PubMed ID: 17887741
[TBL] [Abstract][Full Text] [Related]
9. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
[TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.
Obeng S; Wang H; Jali A; Stevens DL; Akbarali HI; Dewey WL; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1075-1090. PubMed ID: 30156823
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
14. Receptor-selective antagonism of opioid antinociception in female versus male rats.
Craft RM; Tseng AH; McNiel DM; Furness MS; Rice KC
Behav Pharmacol; 2001 Dec; 12(8):591-602. PubMed ID: 11856896
[TBL] [Abstract][Full Text] [Related]
15. Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
Bonner GG; Davis P; Stropova D; Edsall S; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 2000 Feb; 43(4):569-80. PubMed ID: 10691683
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: mu, kappa, and putative epsilon opioid receptor antagonists.
Fujii H; Watanabe A; Nemoto T; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
Bioorg Med Chem Lett; 2009 Jan; 19(2):438-41. PubMed ID: 19042127
[TBL] [Abstract][Full Text] [Related]
17. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
19. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
